2nd Quarter - Report

MARSHALL & POPP, LLC for SUN PHARMACEUTICAL INDUSTRIES, INC.

Period 2nd Quarter 2026 Filed Jul 9, 2026 Signed by Beth Anne Cole

Official filing
Firm
MARSHALL & POPP, LLC
Client
SUN PHARMACEUTICAL INDUSTRIES, INC.
Income
$60,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.

LobbyistCovered position, as disclosed
HAZEN CLAY MARSHALL Policy Director-Senate Majority Leader Mitch McConnell; Staff Director, Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant-Senator Don Nickles
MONICA POPP Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.